Trevena Inc (TRVN)
Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s pipeline includes OLINVYK (oliceridine) injection, a G protein biased mu-opioid receptor ligand being developed for moderate-to-severe acute pain; TRV734, a small-molecule G protein biased MOR ligand that has completed phase I studies for moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator under development for chronic pain management. Trevena was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. The company’s common stock trades on OTC Markets under the symbol TRVN.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-TRVN
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
—
|
—
|
—
|
10.642 K
|
—
|
—
|
—
|
—
|
—
|
—
|